Phase I Study of Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors.

Trial Profile

Phase I Study of Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Sep 2017

At a glance

  • Drugs Monoclonal antibody 3F8 (Primary)
  • Indications Neuroblastoma; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Sep 2017 Planned End Date changed from 1 Aug 2017 to 1 Aug 2018.
    • 05 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2018.
    • 15 Feb 2016 Planned number of patients changed from 72 to 74 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top